Literature DB >> 10716207

Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea.

C L Limebeer1, L A Parker.   

Abstract

Reliable animal models of nausea are necessary to better understand the neurobiology of nausea and to assess treatment effectiveness. We present such a model based on conditioned rejection reactions in rats. Our results demonstrate that delta-9-tetrahydrocannabinol (THC), a treatment reported to reduce chemotherapy-induced nausea in humans, also reduces conditioned rejection reactions in rats. Rats were administered THC or vehicle prior to a pairing of saccharin solution with cyclophosphamide or saline during conditioning and/or prior to test. THC interfered with the establishment of cyclophosphamide-induced conditioned rejection during conditioning and with the expression of conditioned rejection during testing. Our results confirm that the conditioned rejection reaction in the rat is a useful animal model of nausea.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10716207     DOI: 10.1097/00001756-199912160-00009

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  22 in total

1.  Extinction of a saccharin-lithium association: assessment by consumption and taste reactivity.

Authors:  Raúl Cantora; Matías López; Luis Aguado; Shadna Rana; Linda A Parker
Journal:  Learn Behav       Date:  2006-02       Impact factor: 1.986

Review 2.  Regulation of nausea and vomiting by cannabinoids.

Authors:  Linda A Parker; Erin M Rock; Cheryl L Limebeer
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus.

Authors:  E M Rock; R L Kopstick; C L Limebeer; L A Parker
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.

Authors:  Erin M Rock; Martin A Sticht; Marnie Duncan; Colin Stott; Linda A Parker
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

5.  The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat.

Authors:  Erin M Rock; Cheryl L Limebeer; Raphael Mechoulam; Daniele Piomelli; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2007-11-09       Impact factor: 4.530

6.  Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.

Authors:  E M Rock; L A Parker
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 7.  Taste avoidance and taste aversion: evidence for two different processes.

Authors:  Linda A Parker
Journal:  Learn Behav       Date:  2003-05       Impact factor: 1.986

8.  Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.

Authors:  Linda A Parker; Page Burton; Robert E Sorge; Christine Yakiwchuk; Raphael Mechoulam
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

9.  Effect of selective inhibition of monoacylglycerol lipase (MAGL) on acute nausea, anticipatory nausea, and vomiting in rats and Suncus murinus.

Authors:  Linda A Parker; Micah J Niphakis; Rachel Downey; Cheryl L Limebeer; Erin M Rock; Martin A Sticht; Heather Morris; Rehab A Abdullah; Aron H Lichtman; Benjamin F Cravatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-03       Impact factor: 4.530

10.  Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).

Authors:  Linda A Parker; Magdalena Kwiatkowska; Page Burton; Raphael Mechoulam
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.